Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to manufacture the antibody provides a competitive advantage compared to competing biosimilar developers.
Metabolic control of CHOBC® for production of biologics
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
SGGW and Polpharma Biologics launch postgraduate studies for biotechnology enthusiasts
In October, together with the Warsaw University of Life Sciences [SGGW], we are launching the new Polpharma...
Polpharma Biologics na CEBioForum 2024
CEBioForum 2024 is an annual international conference for the biotechnology sector and also the largest...
Konstantin Matentzoglu for Puls Biznesu
We are expanding our research portfolio - that's what you'll read about in Puls Biznesu. Editor Marcel...